Hypertension Clinical Trials

Find Hypertension Clinical Trials Near You

Study of the Prevalence of Diabetes and Pre-diabetes in Réunion Island

Status: Recruiting
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

In view of the new priority given to diabetes in Réunion and the implementation of an ambitious plan to combat the disease at regional level, which includes the identification and management of pre-diabetes, the need for up-to-date data on the extent of these 2 diseases (diabetes and pre-diabetes) has become essential. These two diseases have known risk factors: age, overweight, obesity, high waist circumference, family history, hypertension, eating habits and physical activity, all of which form part of a risk score for developing diabetes: the Findrisk recommended by the Haute Autorité de Santé for identifying people at risk of diabetes. Given the specific population characteristics of Réunion compared with Finland, where this score has been validated, it would seem important to be able to measure these risk indicators in the population as a function of carbohydrate status in order to check that the proposed thresholds are appropriate for the population of Réunion. Finally, cardiovascular risk has been described as early as the pre-diabetes stage. Given the young age of onset of diabetes in Réunion and the high proportion of diagnoses of diabetes made following the occurrence of a cardiovascular complication, the study of the prognosis of carbohydrate status on the occurrence of complications using the social security information system will be offered on a voluntary basis to study subjects (via a probabilistic social security link).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:

• Have lived in Réunion island for at least one year

• Be aged between 18 and 75

• Affiliated to or benefiting from a social security scheme

• Free, informed and signed consent

Contact Information
Primary
Catherine MARIMOUTOU, MD, PhD
catherine.marimoutou@chu-reunion.fr
+262 (0)262 90 50 50
Backup
Florence LEFEBVRE D'HELLENCOURT
florence.lefebvre-dhellencourt@chu-reunion.fr
+262 262 75 34 71
Time Frame
Start Date: 2025-04-02
Estimated Completion Date: 2026-12
Participants
Target number of participants: 2000
Treatments
Other: Detection of glycaemic anomalies
Related Therapeutic Areas
Sponsors
Collaborators: Agence Régionale de Santé de La Réunion
Leads: Centre Hospitalier Universitaire de la Réunion

This content was sourced from clinicaltrials.gov